Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 159Neoplasms 116Carcinoma, Non-Small-Cell Lung 91Colorectal Neoplasms 86Prostatic Neoplasms 85Lung Neoplasms 78Leukemia, Myeloid, Acute 54Carcinoma, Hepatocellular 52Pancreatic Neoplasms 46Neoplasm Metastasis 44Multiple Myeloma 38Recurrence 35Triple Negative Breast Neoplasms 31Squamous Cell Carcinoma of Head and Neck 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Ovarian Neoplasms 29Melanoma 28Uterine Cervical Neoplasms 27Stomach Neoplasms 27Glioblastoma 27Brain Neoplasms 27Rectal Neoplasms 25Head and Neck Neoplasms 25Small Cell Lung Carcinoma 23Carcinoma, Renal Cell 23Endometrial Neoplasms 20Lymphoma, B-Cell 19Glioma 19Sarcoma 18Lymphoma, Follicular 18

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × ALK Positive Non-small Cell Lung Cancer × 90 days × Clear all
NCT07617337 2026-06-01

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Chugai Pharmaceutical

Phase 1 Not yet recruiting
102 enrolled
Thoracic

ALK Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡